Key points for investors:
- Q1 2026 performance beat expectations across revenue, medical margin and adjusted EBITDA. Management raised full-year 2026 guidance. Using midpoint guidance, company now expects ~ $5.7B revenue, ~$375M medical margin and ~$25M adjusted EBITDA.
- Membership: Medicare Advantage membership declined year-over-year (426k vs 491k) due to measured growth, prior market exits and disciplined contracting; ACO REACH membership was 110k. Some members remain under care-coordination fee arrangements.
- Data, AI and clinical programs: agilon implemented an enhanced data pipeline (member-level clinical/claims and risk scores for ~85% of members) and is integrating generative AI into physician workflows. These capabilities, plus scaled clinical pathways (CHF deployed across ~90% of markets) are driving earlier detection, improved guideline-directed therapy rates, and better forecasting.
- Risk adjustment and revenue: Improved visibility led to a larger-than-expected increase in estimated risk scores for 2025/2026 (now 1.5% full-year net of V28 vs prior 0.4%), contributing to revenue upside.
- Medical cost trends and reserving: Favorable development in H2 2025; company is conservatively maintaining a full-year net cost trend outlook of ~7% for 2026. Part D reserving remains conservative given limited reconciliations until Q3. Recorded a 7.4% cost trend for Q1 given limited paid-claims visibility.
- ACO REACH and CMS: Strong ACO REACH Q1 adjusted EBITDA performance ($27M) benefited from CMS removing fraudulent urinary catheter and suspect skin substitute costs from 2025 benchmarks. Management is evaluating future participation choices (LEAD vs MSSP) for 2027.
- Payer contracting and margins: Finalized 2026 payer contracts; started 2027 contracting with a disciplined, profitability-focused approach (focus areas include percent-of-premium, Part D exposure reduction and carve-outs/capture corridors). Management believes CMS’ 2027 effective growth rate provides a reasonable starting point (cited ~5.33%).
- Balance sheet and corporate: Cash and marketable securities of $303M plus $47M cash held by ACO entities. Year-end cash expected to be at least $125M. Reverse stock split executed at quarter end. Leadership: Tim O'Rourke joins as CEO (effective May 7).
- Execution focus: Management emphasizes disciplined execution—data/AI, clinical pathways, payer contracting and cost control—to drive durable margin expansion and sustainable performance.
Sign In
Buy AGL
